

Date : 08.11.2024

To,
The Manager - Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E), Mumbai- 400 051

Symbol - NEPHROCARE

Sub: Outcome of Board Meeting dated 8th November, 2024

Ref: Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 29(1)(a), 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors of the Company at its meeting held today 8th November, 2024, (commenced at 1530 Hours and concluded at 1730 Hours) interalia, approved the following;

- 1) Approval of the Unaudited Financial Results of the Company along with the Limited Review report for the half year ended 30th September, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- 2) Approval of Utilization Certificate of IPO Proceeds from M/s. K. K. Chanani & Associates, Statutory Auditor of the Company.
- 3) Adoption of various Policies as per regulation 46 of SEBI (LODR) Regulations, 2015. The same shall be uploaded in the website of the Company.
- 4) Approval for Mr. Sougata Sengupta, Company Secretary, to hold Independent Directorship in other companies, in accordance with Section 203 of the Companies Act.
- 5) Discussion on NSE Letter Regarding delayed Submission of Financial Results of first quarter for FY 2023-24. The Board also noted that application for waiver of penalty is pending before NSE.
- 6) The Board noted the Related Party Transactions of the Company.



Office Address

JC 18 Ln, JC Block, 5th & 6th Floor, Sec III,
Bidhannagar, Kolkata 700106

 nephrocureindia.com
 support@nephrocureindia.com
 08069 841500

- 7) Noting of resignation of Mr. Somnath Chakraborty as CEO of Company. Mr Somnath's last working day with the Company was 30th September 2024, the same was intimated to NSE on receipt of resignation letter.
- 8) The Board noted the approval for giving authorisation to Mr. Arnab Majumder, COO of the Company as an Authorised Signatory to specific Bank Account of Company up to an amount not exceeding Rs. 25 Lacks.
- 9) The Board noted the request to be sent to Bank(s) to give online viewing rights for account maintained with ICICI Bank.
- 10) The Board noted the approval granted for authorising Mr. Arnab Majumdar, Chief Operating Officer (COO) of the Company for applying New MD-5 Retail License for Indoor & Retail Sale of Manufactured Drugs.
- 11) The Board noted and approved authorisation given to Mr. Pratim Sengupta, Managing Director or Mr. Sougata Sengupta, Company Secretary to negotiate, execute the lease agreement for sitting up a new unit at Badra, Mumbai.

The Board meeting commenced at 1530 Hours (IST) and concluded at 1730 Hours (IST).

The above announcements are also being made available on the website of the Company at www.nephrocareindia.com.

Thanking you,

Yours Faithfully,

For **Nephro Care India Limited**



Sougata Sengupta
Company Secretary & Compliance Officer
Membership No. 17860